HOME >> BIOLOGY >> NEWS
Cell pathways' SAANDs compounds enhance antitumor effects of Taxol™ in rodent models of breast cancer

HORSHAM, PA (April 3, 2000) -- CP461, a second generation selective apoptotic antineoplastic drug (SAAND) compound, under development by Cell Pathways, Inc. (Nasdaq: CLPA), significantly enhanced the anti-tumor activity of Taxol™ (paclitaxel) in a classic mouse model of human breast cancer, according to a presentation by company scientists this week at the annual meeting of the American Association for Cancer Research (AACR).

Cell Pathways researchers implanted human breast tumor cell lines in immunosuppressed (nude) mice and divided them into treatment and control groups. The treated mice were divided into multiple groups receiving either (1) five days of intravenous paclitaxel alone, (2) 14 days of oral CP461 at a subtherapeutic dose based on previous single agent studies, or (3) the drugs in combination. The researchers then observed the mice for 45 days. The mice tolerated the drug treatments well, whether they received the single agents or combination therapy, and there were no differences in unscheduled deaths or weight loss between the groups. The researchers observed that the reduction in the size of the tumors achieved by the combination of paclitaxel and CP461 was significantly greater (p=0.03) than that achieved with paclitaxel alone during treatment and during the month after discontinuation of treatment.

"This research suggests that CP461, given in combination with paclitaxel, may potentially increase paclitaxel1s efficacy in breast cancer without adding any additional side-effects," said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways. "CP461 is nearing completion of a Phase Ib safety study as a single agent in cancer patients. Based on these preclinical results, we plan to investigate CP461 as a single agent cancer therapy and in combination cancer chemotherapeutic studies in the near future."

CP461 is a second generation SAAND based on the mechanism of action of Aptosyn (exisulind). Aptosyn™ i
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2

Related biology news :

1. Aptosyn™ (exisulind) and other SAANDs target early event in cancer; AACR presentations detail novel apoptotic pathway
2. Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms
3. Scientists identify compounds that mimic calorie restriction
4. New, non-radioactive screen for antimalarial compounds
5. Three molecular-targeted compounds show promise against cancers
6. Emory scientists find anti-tumor compounds in magnolia cones
7. Mouse model links alcohol intake to marijuana-like brain compounds
8. Iron-binding compounds decrease body odor
9. New evidence for organic compounds in deep space
10. Researchers identify compounds that might help in spinal cord repair
11. Selected estrogen compounds modify risks of vein clotting, a response to hormone replacement theraphy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/27/2018)... Calif. (PRWEB) , ... November 27, 2018 , ... ... Sons. The companies have worked together to integrate the LabArchives Classroom Edition ... The combined offering will be available beginning January of 2019. ...
(Date:11/23/2018)... ... 23, 2018 , ... uBiome, the leader in microbial genomics, ... Oppenheimer Center for Neurobiology of Stress and Resilience, to its Medical Advisory Board. ... Mayer will bring to uBiome his expertise on the connections between the digestive ...
(Date:11/20/2018)... NEW YORK (PRWEB) , ... November 19, 2018 ... ... Report by Applications (academic research tools, drug development, agriculture, human clinical therapeutics, ... and plant breeding products), by Technology (drug compound and target screening, and agriculture ...
Breaking Biology News(10 mins):
(Date:11/20/2018)... SPRINGS, Ga. (PRWEB) , ... November 19, 2018 , ... ... now receive custom dental implants from Dr. Dan Myers at THE DENTIST ... offering dental implant placement and restorations for the last 20 years. He now offers ...
(Date:11/13/2018)... ... November 12, 2018 , ... AseptiScope(TM), Inc. announces ... large U.S. studies, published last week, confirm pose a significant health risk. ... (AJIC) conclude that stethoscopes are often improperly or rarely disinfected. In the AJIC ...
(Date:11/11/2018)... ... 09, 2018 , ... Triple W, an innovator of connected health devices, today ... for DFree ®, the first health tech wearable device for incontinence that monitors ... the bathroom. The announcement was made during CES Unveiled New York, an invite-only tech ...
(Date:11/7/2018)... Mass. (PRWEB) , ... November 07, 2018 , ... ... system for algae at AzCATI, the Arizona Center for Algae Technology and Innovation at ... facilitate process development and trials for those involved with algal and predator control applications. ...
Breaking Biology Technology:
Cached News: